mavoglurant

Mavoglurant is an investigational small molecule drug that acts as a selective negative allosteric modulator (antagonist) of the metabotropic glutamate receptor 5 (mGluR5). It was originally developed by Novartis and has been studied for several neuropsychiatric and neurological conditions, including fragile X syndrome, Parkinson's disease (specifically levodopa-induced dyskinesia), obsessive-compulsive disorder (OCD), alcohol use disorder, cocaine use disorder, Huntington's disease chorea, anxiety disorders, gastroesophageal reflux disease (GERD), and smoking withdrawal. Mavoglurant reached phase II/III clinical trials in some indications but failed to demonstrate efficacy in pivotal studies for fragile X syndrome and levodopa-induced dyskinesia. Development for these indications was discontinued by Novartis. More recently, Stalicla acquired rights to the drug from Novartis to pursue development in substance-use disorders and neurodevelopmental disorders[3][4][5][6][9].

Other names

543906-09-8mavoglurant [INN]